KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Convertible Debt (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Convertible Debt data on record, last reported at $629.3 million in Q1 2025.

  • For Q1 2025, Convertible Debt rose 0.5% year-over-year to $629.3 million; the TTM value through Mar 2025 reached $629.3 million, up 0.5%, while the annual FY2024 figure was $565.0 million, 9.65% down from the prior year.
  • Convertible Debt reached $629.3 million in Q1 2025 per IONS's latest filing, up from $565.0 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $629.3 million in Q1 2025 and bottomed at $44.3 million in Q3 2023.
  • Average Convertible Debt over 5 years is $537.5 million, with a median of $618.7 million recorded in 2021.
  • Peak YoY movement for Convertible Debt: crashed 92.87% in 2023, then soared 1317.45% in 2024.
  • A 5-year view of Convertible Debt shows it stood at $619.1 million in 2021, then increased by 0.38% to $621.5 million in 2022, then grew by 0.63% to $625.4 million in 2023, then decreased by 9.65% to $565.0 million in 2024, then rose by 11.38% to $629.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Convertible Debt were $629.3 million in Q1 2025, $565.0 million in Q4 2024, and $627.7 million in Q3 2024.